• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭自我护理管理系统的成本效益

Cost-Effectiveness of the Self-Care Management System for Heart Failure.

作者信息

Nakane Eisaku, Kato Takao, Tanaka Nozomi, Idouji Makoto, Yamamoto Yuki, Saitou Wataru, Hamaguchi Toka, Yano Mariko, Harita Takeshi, Yamaji Yuhei, Fukuda Hiroki, Haruna Tetsuya, Inoko Moriaki

机构信息

Cardiovascular Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital Osaka Japan.

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine Kyoto Japan.

出版信息

Circ Rep. 2024 Dec 7;7(1):31-36. doi: 10.1253/circrep.CR-24-0088. eCollection 2025 Jan 10.

DOI:10.1253/circrep.CR-24-0088
PMID:39802132
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11711784/
Abstract

BACKGROUND

We recently reported that the self-care management system for heart failure (HF) decreased re-hospitalization for HF. In the present study we estimate the cost-effectiveness of this system.

METHODS AND RESULTS

We retrospectively enrolled 569 consecutive patients who were admitted for HF treatment at Kitano Hospital. In the present analysis, we sought to compare cardiovascular healthcare costs and the incremental cost-effective ratio (ICER), expressed as the cost per quality-adjusted life-years (QALY) gained, between patients using the self-care management system (n=153) and those not using the system (n=153) after propensity-score matching. To calculate the QALY, we used the New York Heart Association class and the corresponding scores of quality of life in every 3 months. The healthcare costs of cardiovascular disease were ¥129,747,016 in the user group and ¥156,427,032 in the non-user group, where 24 and 43 patients were hospitalized, respectively. The cost of this new system was ¥50,000 in the user group. The total costs were ¥129,797,016 in the user group and ¥156,427,032 in the non-user group. By using the system, the QALY increased from 0.653 to 0.686. The ICER was below 0 and the system was interpreted as cost-effective.

CONCLUSIONS

Use of the self-care management system is likely to be a cost-effective treatment for HF with the increase in QALY and the decrease in healthcare costs.

摘要

背景

我们最近报告称,心力衰竭(HF)自我护理管理系统降低了HF的再住院率。在本研究中,我们评估了该系统的成本效益。

方法与结果

我们回顾性纳入了569例在北野医院因HF治疗入院的连续患者。在本分析中,我们试图比较倾向得分匹配后使用自我护理管理系统的患者(n = 153)和未使用该系统的患者(n = 153)之间的心血管医疗保健成本以及增量成本效益比(ICER),以每获得的质量调整生命年(QALY)的成本来表示。为了计算QALY,我们使用纽约心脏协会分级以及每3个月相应的生活质量评分。用户组心血管疾病的医疗保健成本为129747016日元,非用户组为156427032日元,两组分别有24例和43例患者住院。用户组中该新系统的成本为50000日元。用户组的总成本为129797016日元,非用户组为156427032日元。通过使用该系统,QALY从0.653提高到0.686。ICER低于0,该系统被认为具有成本效益。

结论

使用自我护理管理系统可能是一种对HF具有成本效益的治疗方法,可提高QALY并降低医疗保健成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/40bf4a8cfff4/circrep-7-31-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/ead2e19750f4/circrep-7-31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/5a089b38d7e3/circrep-7-31-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/ad44c75f3ce3/circrep-7-31-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/40bf4a8cfff4/circrep-7-31-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/ead2e19750f4/circrep-7-31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/5a089b38d7e3/circrep-7-31-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/ad44c75f3ce3/circrep-7-31-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ac/11711784/40bf4a8cfff4/circrep-7-31-g004.jpg

相似文献

1
Cost-Effectiveness of the Self-Care Management System for Heart Failure.心力衰竭自我护理管理系统的成本效益
Circ Rep. 2024 Dec 7;7(1):31-36. doi: 10.1253/circrep.CR-24-0088. eCollection 2025 Jan 10.
2
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.沙库巴曲缬沙坦用于心力衰竭管理的健康和经济评估。
JAMA Cardiol. 2023 Nov 1;8(11):1041-1048. doi: 10.1001/jamacardio.2023.3216.
3
Real-time pulmonary artery pressure monitoring in heart failure patients: an updated cost-effectiveness analysis.心力衰竭患者实时肺动脉压监测:一项更新的成本效益分析。
ESC Heart Fail. 2023 Oct;10(5):3046-3054. doi: 10.1002/ehf2.14496. Epub 2023 Aug 17.
4
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.沙库巴曲缬沙坦与依那普利治疗射血分数降低的心力衰竭患者的成本效益
J Med Econ. 2018 Feb;21(2):174-181. doi: 10.1080/13696998.2017.1387119. Epub 2017 Oct 10.
5
Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.维立西呱用于治疗射血分数降低的心力衰竭恶化事件后的心力衰竭:中国医疗服务提供者视角的成本效益分析
Clin Drug Investig. 2023 Apr;43(4):241-250. doi: 10.1007/s40261-023-01253-y. Epub 2023 Mar 16.
6
Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands.荷兰慢性心力衰竭患者应用植入式肺动脉压力监测传感器(CardioMEMS-HF 系统)进行远程血液动力学监测的成本效益分析。
Eur J Heart Fail. 2024 May;26(5):1189-1198. doi: 10.1002/ejhf.3213. Epub 2024 Apr 1.
7
Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.用于治疗心律失常的植入式心脏复律除颤器和用于治疗心力衰竭的心脏再同步治疗:系统评价与经济学评估
Health Technol Assess. 2014 Aug;18(56):1-560. doi: 10.3310/hta18560.
8
The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective.心力衰竭患者实时肺动脉压监测的成本效益:欧洲视角
Eur J Heart Fail. 2017 May;19(5):661-669. doi: 10.1002/ejhf.747. Epub 2017 Feb 7.
9
Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community.在一个种族多元化的城市社区中,由护士主导的心力衰竭疾病管理的成本效益。
Ann Intern Med. 2008 Oct 21;149(8):540-8. doi: 10.7326/0003-4819-149-8-200810210-00006.
10
Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia.马来西亚射血分数降低的心力衰竭患者中血管紧张素受体脑啡肽酶抑制剂与血管紧张素转换酶抑制剂的成本效益分析
Value Health Reg Issues. 2025 May 3;48:101118. doi: 10.1016/j.vhri.2025.101118.

引用本文的文献

1
Rationale and Protocol of the Registry for Contemporary Medical Management of Chronic Heart Failure With Mildly Reduced and Preserved Ejection Fraction - The PARACLETE Study.射血分数轻度降低和保留的慢性心力衰竭当代医学管理登记研究的原理与方案——帕拉克莱特研究
Circ Rep. 2025 May 14;7(6):491-496. doi: 10.1253/circrep.CR-24-0138. eCollection 2025 Jun 10.

本文引用的文献

1
Cardiovascular disease, a major global burden: Epidemiology of stroke and ischemic heart disease in Japan.心血管疾病是一项重大的全球负担:日本的中风和缺血性心脏病流行病学
Glob Health Med. 2021 Dec 31;3(6):358-364. doi: 10.35772/ghm.2020.01113.
2
Association between induction of the self-management system for preventing readmission and disease severity and length of readmission in patients with heart failure.心力衰竭患者自我管理系统的诱导与疾病严重程度和再入院时间的关系。
BMC Res Notes. 2021 Dec 18;14(1):452. doi: 10.1186/s13104-021-05864-6.
3
Association of Previous Hospitalization for Heart Failure With Increased Mortality in Patients Hospitalized for Acute Decompensated Heart Failure.
既往因心力衰竭住院与急性失代偿性心力衰竭住院患者死亡率增加的关联。
Circ Rep. 2019 Oct 26;1(11):517-524. doi: 10.1253/circrep.CR-19-0054.
4
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review.心力衰竭患者的健康状态效用值:系统文献回顾。
Pharmacoeconomics. 2021 Feb;39(2):211-229. doi: 10.1007/s40273-020-00984-6. Epub 2020 Nov 30.
5
Association of the induction of a self-care management system with 1-year outcomes in patients hospitalized for heart failure.心力衰竭住院患者自我护理管理系统的诱导与 1 年结局的关联。
J Cardiol. 2021 Jan;77(1):48-56. doi: 10.1016/j.jjcc.2020.07.015. Epub 2020 Aug 2.
6
Hospitalization Costs for Patients With Acute Congestive Heart Failure in Japan.日本急性充血性心力衰竭患者的住院费用。
Circ J. 2019 Apr 25;83(5):1025-1031. doi: 10.1253/circj.CJ-18-1212. Epub 2019 Mar 26.
7
Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan.日本心血管疾病治疗的成本效益分析。
Int Heart J. 2017 Dec 12;58(6):847-852. doi: 10.1536/ihj.17-365. Epub 2017 Nov 17.
8
Comprehensive Cost of Illness of Three Major Diseases in Japan.日本三大疾病的综合疾病成本。
J Stroke Cerebrovasc Dis. 2017 Sep;26(9):1934-1940. doi: 10.1016/j.jstrokecerebrovasdis.2017.06.022. Epub 2017 Jul 13.
9
Containing the Cost of Heart Failure Management: A Focus on Reducing Readmissions.控制心力衰竭管理成本:聚焦于减少再入院率。
Heart Fail Clin. 2017 Jan;13(1):21-28. doi: 10.1016/j.hfc.2016.07.002.
10
Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials.药物依从性干预可改善心力衰竭死亡率和再入院率:对照试验的系统评价和荟萃分析
J Am Heart Assoc. 2016 Jun 17;5(6):e002606. doi: 10.1161/JAHA.115.002606.